Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MLN0002 induction and maintenance study in moderate to severe Crohn's disease
NL-OMON33754Phase 3Active, not recruiting
- Sponsor
- Takeda
- Start
- Oct 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of vedolizumab in Crohn's disease (6 arms), sponsored by Takeda. Primary endpoints: Clinical remission at Week 6 and Clinical remission at Week 52. Started Oct 2009; status: active, not recruiting.
02
Drugs
vedolizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON33754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33754.